HC Wainwright Reiterates Neutral Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports.

Separately, Robert W. Baird lowered their price objective on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Agenus has an average rating of “Hold” and a consensus price target of $8.75.

Agenus Stock Down 4.3 %

Agenus stock opened at $1.78 on Tuesday. The business has a 50-day simple moving average of $3.14 and a 200 day simple moving average of $3.75. Agenus has a 52 week low of $1.65 and a 52 week high of $19.69. The stock has a market cap of $41.76 million, a price-to-earnings ratio of -0.16 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping the consensus estimate of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to analysts’ expectations of $30.09 million. On average, research analysts anticipate that Agenus will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 4,924 shares during the period. HighTower Advisors LLC increased its holdings in Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares during the period. State Street Corp raised its position in Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in Agenus in the 3rd quarter worth approximately $55,000. Finally, Point72 DIFC Ltd grew its position in shares of Agenus by 380.0% in the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after buying an additional 11,542 shares during the last quarter. 61.46% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.